SYRE Spyre Therapeutics, Inc.
$90.95
Spyre Therapeutics, Inc. (SYRE) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
Insider signal
In line
Selling ran in line with SYRE's own trailing one-year pace, with 8% of sale value under a prearranged plan.
Cluster activity
0 buyers in the last 30 days
0 buyers in the last 90 days
7 sellers in the last 90 days
Insiders buying
0
0 transactions
Insiders selling
7
79 transactions
Purchases
$0
0 shares
Sales
$436.7M
5,219,870 shares
Net activity
-$436.7M
purchases less sales
How much of that selling was preplanned? 8% planned / 92% discretionary
10b5-1 plan sales
$34.1M
75 transactions · 501,857 shares
Discretionary sales
$402.6M
4 transactions · 4,718,013 shares
Largest single sale: $399.7M.
Where they traded
Buy
Sell
Dot area is proportional to transaction value.
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Burrows Scott L | Chief Financial Officer | Sell | 18,232 | $89.35 | $1.6M | 79,762 −18.6% of holding | |
| King-Jones Heidy | See Remarks | Sell 10b5-1 | 400 | $90.00 | $36.0K | 2,845 −12.3% of holding | |
| King-Jones Heidy 4 fills | See Remarks | Sell 10b5-1 | 27,999 | $87.31 | $2.4M | 25,999 −51.9% of holding | |
| Turtle Cameron 4 fills | Chief Executive Officer | Sell 10b5-1 | 15,000 | $87.29 | $1.3M | 565,040 −2.6% of holding | |
| Burrows Scott L 4 fills | Chief Financial Officer | Sell 10b5-1 | 7,500 | $87.31 | $654.8K | 104,594 −6.7% of holding | |
| Albers Jeffrey W. 3 fills | Director | Sell 10b5-1 | 23,000 | $104.53 | $2.4M | 19,360 −54.3% of holding | |
| Turtle Cameron 5 fills | Chief Executive Officer | Sell 10b5-1 | 15,000 | $95.51 | $1.4M | 581,740 −2.5% of holding | |
| Burrows Scott L 3 fills | Chief Financial Officer | Sell 10b5-1 | 7,500 | $95.57 | $716.8K | 100,394 −7% of holding | |
| Turtle Cameron 3 fills | Chief Executive Officer | Sell 10b5-1 | 15,000 | $87.69 | $1.3M | 587,364 −2.5% of holding | |
| Sloan Sheldon 2 fills | Chief Medical Officer | Sell 10b5-1 | 8,334 | $87.70 | $730.9K | 1,834 −82% of holding | |
| Burrows Scott L 2 fills | Chief Financial Officer | Sell 10b5-1 | 7,500 | $87.74 | $658.0K | 99,719 −7% of holding | |
| Burrows Scott L 2 fills | Chief Financial Officer | Sell | 15,000 | $87.13 | $1.3M | 107,994 −12.2% of holding | |
| Sell | 4,684,781 | $85.31 | $399.7M | None left | |||
| HENDERSON MICHAEL THOMAS | Director | Sell 10b5-1 | 20,000 | $100.00 | $2.0M | 68,606 −22.6% of holding | |
| Sloan Sheldon | Chief Medical Officer | Sell 10b5-1 | 8,333 | $75.00 | $625.0K | None left | |
| Turtle Cameron 3 fills | Chief Executive Officer | Sell 10b5-1 | 15,000 | $70.43 | $1.1M | 608,983 −2.4% of holding | |
| Burrows Scott L 3 fills | Chief Financial Officer | Sell 10b5-1 | 7,500 | $71.06 | $532.9K | 103,693 −6.7% of holding | |
| HENDERSON MICHAEL THOMAS 4 fills | Director | Sell 10b5-1 | 80,000 | $74.40 | $6.0M | 166,202 −32.5% of holding | |
| Sloan Sheldon 7 fills | Chief Medical Officer | Sell 10b5-1 | 78,333 | $71.50 | $5.6M | 57,027 −57.9% of holding | |
| Turtle Cameron 6 fills | Chief Executive Officer | Sell 10b5-1 | 15,000 | $71.37 | $1.1M | 622,240 −2.4% of holding | |
| Burrows Scott L | Chief Financial Officer | Sell 10b5-1 | 12,500 | $71.37 | $892.1K | 97,994 −11.3% of holding | |
| Turtle Cameron 2 fills | Chief Executive Officer | Sell 10b5-1 | 15,000 | $49.33 | $739.9K | 630,196 −2.3% of holding | |
| Sloan Sheldon | Chief Medical Officer | Sell 10b5-1 | 7,958 | $50.00 | $397.9K | None left | |
| Burrows Scott L 2 fills | Chief Financial Officer | Sell 10b5-1 | 7,500 | $49.34 | $370.1K | 99,294 −7% of holding | |
| Burrows Scott L 2 fills | Chief Financial Officer | Sell 10b5-1 | 2,500 | $40.65 | $101.6K | 98,194 −2.5% of holding | |
| Turtle Cameron 2 fills | Chief Executive Officer | Sell 10b5-1 | 15,000 | $42.19 | $632.9K | 651,640 −2.3% of holding | |
| Turtle Cameron 2 fills | Chief Executive Officer | Sell 10b5-1 | 15,000 | $32.80 | $492.0K | 671,583 −2.2% of holding | |
| Turtle Cameron 3 fills | Chief Executive Officer | Sell 10b5-1 | 15,000 | $30.68 | $460.1K | 674,198 −2.2% of holding | |
| Turtle Cameron 2 fills | Chief Executive Officer | Sell 10b5-1 | 15,000 | $29.02 | $435.4K | 690,912 −2.1% of holding | |
| Turtle Cameron 2 fills | Chief Executive Officer | Sell 10b5-1 | 45,000 | $23.33 | $1.0M | 718,752 −5.9% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.